Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 September 2019 | Story Cornelius Hagenmeier (Director: UFS International Office)

The management of the University of the Free State (UFS) is deeply concerned about the xenophobic and afrophobic attacks presently occurring in our country. Xenophobia is the ‘fear and hatred of strangers or foreigners or of anything that is strange or foreign’ (Merriam-Webster Dictionary), whereas afrophobia can be understood as the ‘fear and hatred of the cultures and people of Africa’.

The UFS strongly condemns all forms of xenophobic and afrophobic actions and thought and expresses its solidarity with the members of the University community hailing from other regions of the African continent and the world. The UFS is committed to promoting diversity, social justice, inclusivity, and transformation. Its University community is united in its diversity. The UFS cherishes diversity as a catalyst for positive change, innovative research, and cutting-edge teaching and learning. Xenophobic actions, threats or statements will never be tolerated at the UFS. The UFS is committed to nurturing and entrenching a human-rights culture and advocating human rights both within the context of the University and beyond.

Xenophobia, afrophobia and discrimination jeopardise the process of internationalisation at the University. They limit the international and multicultural exposure of our students, which are important to achieve graduate attributes and specifically to develop students’ international and intercultural competence. The UFS is strategically strengthening its collaborations and partnerships in Africa and beyond. It recognises the positive force of diversifying the knowledge paradigms with which it interacts. International staff members, postdoctoral fellows, and students make a significant contribution to the academic project, scholarship traditions, and intellectual diversity of the University. The management of the UFS will do all in its power to ensure the wellbeing of all members of its international University community.



Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: + 27 51 401 2584 | +27 51 401 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393


News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept